<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000237.v1.p1" parentStudy="phs000237.v1.p1" createDate="2010-01-20" modDate="2011-10-24">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Rex Chisholm, PhD</td><td>Northwestern University Feinberg School of Medicine, Chicago, IL, USA</td></tr>
		<tr><td>Funding Source</td><td>U01-HG004609</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source for Genotyping</td><td>U01-HG004424</td><td>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Northwestern NUgene Project: Type 2 Diabetes</StudyNameEntrez>
	<StudyNameReportPage>Northwestern NUgene Project: Type 2 Diabetes</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The ability to correlate genetic variation with disease susceptibility and response to drug therapy depends on genotype      or sequence analysis of large numbers of richly characterized DNA samples.   Eight years agoWe are a part of NHGRI&#39;s      <u><b>e</b></u>lectronic <u><b>M</b></u>edical <u><b>R</b></u>ecords and <u><b>Ge</b></u>nomics (eMERGE) Network,      whose goal is to conduct genome-wide association studies in thousands of individuals using EMR-derived phenotypes and      DNA from linked biorepositories.  For eMERGE, Northwestern University (NU) is studying type 2 diabetes as a phenotype.       In addition, in order to explore race differences in the prevalence of type 2 diabetes, NU collaborated with Vanderbilt      University to study a mix of both Caucasian and African-Americans.</p>     <p><b>Northwestern University</b>:  In 2002, Northwestern committed to the development of a DNA repository to serve as a      platform for the identification and validation of genotype-phenotype associations that will impact healthcare.  The NUgene      Project is a repository with longitudinal medical information from participating patients at affiliated hospitals and      outpatient clinics from the Northwestern University Medical Center.  Participants&#39; DNA samples are coupled with data from      a questionnaire (2 versions were used, 1 before and 1 after February 2006, both are included) and continuously updated data      from our Electronic Medical Record (EMR) representing actual clinical care events. Northwestern has a state-of-the art,      comprehensive inpatient and outpatient EMR system of over 2 million patients.  NUgene has broad access to participant data      for all outpatient visits as well as inpatient data via a consolidated data warehouse. NUgene participants consent to      distribution and use of their coded DNA samples and data for a broad range of genetic research by third-party investigators.</p>     <p><b>Vanderbilt University</b>:  BioVU, Vanderbilt&#39;s DNA databank, is an enabling resource for exploration of the relationships      among genetic variation, disease susceptibility, and variable drug responses, and represents a key first step in moving the      emerging sciences of genomics and pharmacogenomics from research tools to clinical practice.  BioVU acquires DNA from discarded      blood samples collected from routine patient care. The biobank is linked to de-identified clinical data extracted from      Vanderbilt&#39;s EMR, which forms the basis for phenotype definitions used in genotype-phenotype correlations.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b>T2DM CASE SELECTION FLOWCHART BELOW</b></p> 	<p>Footnotes for T2D case diagram:<br/> 	<b>* Abnormal labs:</b> Random glucose &gt; 200mg/dl, Fasting glucose &gt; 125 mg/dl, or hemoglobin A1c &#8805; 6.5%.<br/> 	<b>** Clinician-entered diagnoses:</b> Encounter or problem list diagnoses only (all other diagnoses in this diagram could also  	include diagnoses in the medical history)</p> 	 	<p><img src="GetImage.cgi?study_id=phs000237&image_name=eMERGEType2Diabetes_image1.GIF" width="900"/></p><br/><br/> 	 	<p><b>T2DM CONTROL SELECTION FLOWCHART BELOW</b></p> 	 	<p><img src="GetImage.cgi?study_id=phs000237&image_name=eMERGEType2Diabetes_image2.GIF" width="900"/></p> 	 	<p><b>Study Population</b><br/>Suitable participant DNA samples were selected from the NUgene and BioVU biobanks, including both 	Caucasian and African-American populations.</p> 	<p><b>Introduction</b><br/>The cases and controls have been defined to avoid confounding by inclusion of cases with type 1 diabetes 	and as much as possible of controls at risk for type 2 diabetes which has not, as yet, manifested itself.  By doing this, 	a potential source of bias has been introduced in that type 2 diabetic subjects who are treated with insulin alone have been 	excluded, although diabetic subjects on insulin together with one of the diabetes medications listed above are eligible 	for inclusion.  This approach may select against type 2 diabetic subjects with more significant degrees of pancreatic beta 	cell failure.</p> 	<p><b>Challenges</b> 		<ol> 			<li>Potential case contamination with T1DM (Type 1 Diabetes Mellitus) and Mature Onset Diabetes of the Young (MODY) patients.</li> 			<li>Potential control contamination with cases.  However, an ICD9 code for T2D is likely for diet controlled patients.  Also, the  			family history exclusion was added to reduce likelihood that patients were too young to have developed the disease yet.</li> 			<li>Restrictions imposed by inclusion criteria for cases.  One difficult area is the problems presented by patients on insulin  			alone with an ICD9 code for type 2 diabetes, as some of these patients could represent individuals with type 1 diabetes which  			has been misclassified as type 2 diabetes because of age of onset, etc.  To address this, we have identified as cases, patients  			who are on insulin alone, AND: have been on a type 2 diabetes medication in the past, or do not have a type 1 DM diagnosis,  			but have at least two visits (on different dates) with the type 2 DM diagnosis in the problem list or in the encounter  			diagnosis.</li> 			<li>Avoiding cases who have medication (e.g., steroid)-induced hyperglycemia.</li> 		</ol> 	</p>   <p><b><u>Identification of T2D Cases: 2 groups</u></b><br/>   Neither group should have T1D diagnosis codes (ICD-9 250.x1 or 250.x3) 		<ol> 			<li><b>Identification of patients who already have a T2D diagnosis</b> 				<ul> 					<li><b>Step 1:</b> Include patients with Type 2 Diabetes diagnosis based on ICD9 codes (excluding those with 					ketoacidosis codes)<br/><br/> 					<i>Table 1: Type 2 Diabetes ICD9 codes meeting inclusion criteria.</i> 					<table border="1"> 						<tr><td><b>Description for type 2 diabetes codes used</b></td><td><b>ICD9 Code</b></td></tr> 						<tr><td>Diabetes with other coma</td><td>250.3</td></tr> 						<tr><td></td><td>250.32</td></tr> 						<tr><td>Diabetes with hyperosmolarity</td><td>250.2</td></tr> 						<tr><td></td><td>250.22</td></tr> 						<tr><td>Diabetes with unspecified complication</td><td>250.9</td></tr> 						<tr><td></td><td>250.92</td></tr> 						<tr><td>Diabetes with other unspecified manifestation</td><td>250.8</td></tr> 						<tr><td></td><td>250.82</td></tr> 						<tr><td>Diabetes with peripheral circulatory disorder</td><td>250.7</td></tr> 						<tr><td></td><td>250.72</td></tr> 						<tr><td>Diabetes with neurological manifestations</td><td>250.6</td></tr> 						<tr><td></td><td>250.62</td></tr> 						<tr><td>Diabetes with opthalmic manifestations</td><td>250.5</td></tr> 						<tr><td></td><td>250.52</td></tr> 						<tr><td>Diabetes with renal manifestations</td><td>250.4</td></tr> 						<tr><td></td><td>250.42</td></tr> 						<tr><td>Diabetes mellitus without mention of complication</td><td>250</td></tr> 						<tr><td></td><td>250.02</td></tr> 					</table>  					</li><br/> 					<li><b>Step 2:</b> Exclude patients (currently) treated <u>only with insulin AND have never been on a type 2 					diabetes medication</u>, and: diagnosed with T1DM, or even if not diagnosed with T1DM, diagnosed with 					T2DM on &lt; 2 dates in an encounter or problem list.<br/><br/> 					<i>Table 2. Prescribed type 2 diabetes medications meeting patient inclusion criteria.</i> 					<table border="1"> 						<tr><td><b>Drug class</b></td><td><b>Brand name</b></td><td><b>Generic name</b></td></tr> 						<tr><td>Sulfonylureas</td><td></td><td>acetohexamide</td></tr> 						<tr><td>Sulfonylureas</td><td></td><td>tolazamide</td></tr> 						<tr><td>Sulfonylureas</td><td>Diabinese</td><td>chlorpropamide</td></tr> 						<tr><td>Sulfonylureas</td><td>Glucotrol</td><td>glipizide</td></tr> 						<tr><td>Sulfonylureas</td><td>Glucotrol XL</td><td>glipizide</td></tr> 						<tr><td>Sulfonylureas</td><td>Micronase</td><td>glyburide</td></tr> 						<tr><td>Sulfonylureas</td><td>Glynase</td><td>glyburide</td></tr> 						<tr><td>Sulfonylureas</td><td>Diabeta</td><td>glyburide</td></tr> 						<tr><td>Sulfonylureas</td><td>Amaryl</td><td>glimepiride</td></tr> 						<tr><td>Meglitinides</td><td>Prandin</td><td>repaglinide</td></tr> 						<tr><td>Meglitinides</td><td>Starlix</td><td>nateglinide</td></tr> 						<tr><td>Biguanides</td><td>Glucophage</td><td>metformin</td></tr> 						<tr><td>Thiazoldinediones</td><td>Avandia</td><td>rosiglitazone</td></tr> 						<tr><td>Thiazoldinediones</td><td>ACTOS</td><td>pioglitazone</td></tr> 						<tr><td>Thiazoldinediones</td><td></td><td>troglitazone</td></tr> 						<tr><td>Alpha-glucosidase inhibitors</td><td>Precose</td><td>acarbose</td></tr> 						<tr><td>Alpha-glucosidase inhibitors</td><td>Glyset</td><td>miglitol</td></tr> 						<tr><td>DPPIV inhibitor</td><td>Januvia</td><td>sitagliptin</td></tr> 						<tr><td>Injectables</td><td>Byetta</td><td>exenatide</td></tr> 					</table><br/> 					<i>Table 3*. Prescribed medications meeting patient exclusion criteria unless one or more of the medications listed  					above is also prescribed:</i> 					<table border="1"> 						<tr><td><b>Drug class</b></td><td><b>Brand name</b></td><td><b>Generic name</b></td></tr> 						<tr><td>Injectables</td><td>Insulin</td><td>Insulin</td></tr> 						<tr><td>Injectables</td><td>Symlin**</td><td>Pramlintide</td></tr> 						<tr><td>Diabetic Insulin Supplies</td><td></td><td></td></tr> 					</table> 					* Limits potential case contamination with T1D patients.<br/> 					** Exclude if patient is on this alone or in combination with insulin only.<br/><br/> 					<i>Table 4. ICD9 codes to exclude type 1 diabetics.</i> 					<table border="1"> 						<tr><td><b>Description for type 1 (juvenile) diabetes codes used</b></td><td><b>ICD9 Code</b></td></tr> 						<tr><td>Diabetes with other coma</td><td>250.31</td></tr> 						<tr><td></td><td>250.33</td></tr> 						<tr><td>Diabetes with hyperosmolarity</td><td>250.21</td></tr> 						<tr><td></td><td>250.23</td></tr> 						<tr><td>Diabetes with unspecified complication</td><td>250.91</td></tr> 						<tr><td></td><td>250.93</td></tr> 						<tr><td>Diabetes with other unspecified manifestation</td><td>250.81</td></tr> 						<tr><td></td><td>250.83</td></tr> 						<tr><td>Diabetes with peripheral circulatory disorder</td><td>250.71</td></tr> 						<tr><td></td><td>250.73</td></tr> 						<tr><td>Diabetes with neurological manifestations</td><td>250.61</td></tr> 						<tr><td></td><td>250.63</td></tr> 						<tr><td>Diabetes with opthalmic manifestations</td><td>250.51</td></tr> 						<tr><td></td><td>250.53</td></tr> 						<tr><td>Diabetes with renal manifestations</td><td>250.41</td></tr> 						<tr><td></td><td>250.43</td></tr> 						<tr><td>Diabetes mellitus without mention of complication</td><td>250.01</td></tr> 						<tr><td></td><td>250.03</td></tr> 						<tr><td>Diabetes mellitus with ketoacidosis</td><td>250.11</td></tr> 						<tr><td></td><td>250.13</td></tr> 					</table>  					</li><br/> 				</ul> 			</li> 			<li><b>Identification of patients who do not yet have a T2D diagnosis</b> 				<ul> 					<li><b>Step 1:</b> Include patients with hemoglobin A1C lab value &#8805; 6.5%, fasting glucose &gt; 125 mg/dl 					or random glucose &gt; 200 mg/dl AND prescribed one of the medications (or combinations thereof) listed in Table 2.</li> 				</ul> 			</li> 		</ol> 	</p> 	<p><b>Identification of T2D Controls:</b><br/><br/> 		<b>Patients must meet all of the following criteria:</b> 		<ol> 			<li>Have had at least 2 clinic visits (face-to-face outpatient clinic encounters).</li> 			<li>Have not been assigned an ICD9 code for diabetes (type 1 or type 2) or any diabetes-related condition 			(See codes from Tables 1, 4, and 5)</li><br/> 				<i>Table  5. ICD9 codes to exclude potential controls (in addition to Table 1).</i> 					<table border="1"> 						<tr><td><b>Description</b></td><td><b>ICD9 Code</b></td></tr> 						<tr><td>Diabetes mellitus type 1 & 2</td><td>250.xx</td></tr> 						<tr><td>Impaired fasting glucose</td><td>790.21</td></tr> 						<tr><td>Impaired oral glucose tolerance test</td><td>790.22</td></tr> 						<tr><td>Abnormal glucose not otherwise specified</td><td>790.2, 790.29</td></tr> 						<tr><td>Abnormal glucose during pregnancy</td><td>648.8x</td></tr> 						<tr><td>Gestational diabetes</td><td>648.0x</td></tr> 						<tr><td>Glycosuria</td><td>791.5</td></tr> 						<tr><td>Dysmetabolic syndrome X</td><td>277.7</td></tr> 						<tr><td>Family history of diabetes mellitus</td><td>V18.0</td></tr> 						<tr><td>Screening for diabetes mellitus</td><td>V77.1</td></tr> 					</table><br/> 			<li>Have not been prescribed insulin or Pramlintide (See Table 3), or any medications for diabetes treatment (See Table 2), 			or diabetic supplies such as those for medication administration or glucose monitoring.</li> 			<li>Do not have a reported (random or fasting) blood glucose &#8805; 110mg/dl and have had at least 1 glucose measurement</li> 			<li>Do not have a reported hemoglobin A1c &#8805; 6.0%</li> 			<li>Do not have a reported family history of diabetes (type 1 or type 2)</li> 		</ol> 	</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Wolf WA, Doyle MJ, Aufox SA, Frezzo TF, Smith ME, Kibbe KE, Chisholm RL" title="DNA Banking Study in an Ethnically Diverse Urban University Hospital" journal="American Journal of Human Genetics. 2003;73:423"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Diabetes Mellitus, Type 2"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Rex Chisholm, PhD</AttName>
			<Institution>Northwestern University Feinberg School of Medicine, Chicago, IL, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01-HG004609</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source for Genotyping">
			<AttName>U01-HG004424</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="The eMERGE Network" url="https://www.mc.vanderbilt.edu/victr/dcc/projects/acc/index.php/Main_Page"/>
		<Url name="NUgene" url="https://www.nugene.org/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p><b>Type 2 Diabetes Time Line</b></p> 	<p> 		<ul> 			<li>October 2002 - NUgene became operational</li> 			<li>January 2008 - Began T2DM phenotyping process </li> 			<li>May/June 2009 - Selected samples to be genotyped</li> 			<li>July 2010 - Samples shipped and received at The Broad Institute</li> 			<li>2010 - Genotyping of samples complete</li> 		</ul> 	</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="0" shortName="NRUP" longName="Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects."/>
		<ConsentGroup groupNum="1" shortName="HR_VU" longName="Health Research - Vanderbilt U"/>
		<ConsentGroup groupNum="2" shortName="HR_NWU" longName="Health Research - Northwestern U"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>nhgridac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-480-2770</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000237.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000237.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000237.v1.p1" FileName="eMERGE_GWAS_DUC_09-23-2011.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health Research - Vanderbilt U</ConsentName>
        <ConsentAbbrev>HR_VU</ConsentAbbrev>
        <UseLimitation>May be used for genetic studies to learn about, prevent, or treat health problems</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Health Research - Northwestern U</ConsentName>
        <ConsentAbbrev>HR_NWU</ConsentAbbrev>
        <UseLimitation>May be used for genetic studies to learn about, prevent, or treat health problems. No Permitted Use: Insurance companies</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>
  <Documents>
    <Document phd="phd003361.1" type="questionnaire" createDate="2011-01-12" modDate="2011-02-22" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003361.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000237.v1.p1&amp;phd=3361">
      <OrigName>NUgene Questionnaire.1.12.06.pdf</OrigName>
      <DisplayName>NUgene Questionnaire 01-12-06</DisplayName>
      <Description>NUgene Questionnaire 01-12-06</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003362.1" type="questionnaire" createDate="2011-01-12" modDate="2011-02-22" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003362.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000237.v1.p1&amp;phd=3362">
      <OrigName>NUgene Questionnaire.02.13.03.pdf</OrigName>
      <DisplayName>NUgene Questionnaire 02-13-03</DisplayName>
      <Description>NUgene Questionnaire 02-13-03</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
    <Document phd="phd003369.1" type="protocol" createDate="2011-01-25" modDate="2011-02-22" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd003369.1" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs000237.v1.p1&amp;phd=3369">
      <OrigName>Questionnaire Code Sheet 1.12.06.fnl.pdf</OrigName>
      <DisplayName>The NUgene Questionnaire Resource Sheet for Questions #12, #13, #14, #15, and #18</DisplayName>
      <Description>The NUgene Questionnaire Resource Sheet for Questions #12, #13, #14, #15, and #18</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
  </Documents>

  <Annotations>
    <DocumentPart phd="phd003361.1" sectionId="V1">
      <phvList>
        <phvRef variableId="158819"/>
        <phvRef variableId="158820"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V18">
      <phvList>
        <phvRef variableId="158821"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V19">
      <phvList>
        <phvRef variableId="158822"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V2">
      <phvList>
        <phvRef variableId="158818"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V24i">
      <phvList>
        <phvRef variableId="158826"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V24j">
      <phvList>
        <phvRef variableId="158826"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003361.1" sectionId="V9">
      <phvList>
        <phvRef variableId="158823"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V1">
      <phvList>
        <phvRef variableId="158819"/>
        <phvRef variableId="158820"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V14">
      <phvList>
        <phvRef variableId="158821"/>
        <phvRef variableId="158822"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V2">
      <phvList>
        <phvRef variableId="158818"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V20k">
      <phvList>
        <phvRef variableId="158826"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V20l">
      <phvList>
        <phvRef variableId="158826"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003362.1" sectionId="V8">
      <phvList>
        <phvRef variableId="158823"/>
      </phvList>
    </DocumentPart>
    <DocumentPart phd="phd003369.1" sectionId="t4">
      <phvList>
        <phvRef variableId="158821"/>
      </phvList>
    </DocumentPart>
  </Annotations>



</Study>

</Studies>

</GaPExchange>
